← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Bioprovar Corporation
Houston, TX
$1,237,146
Total funding
2
Grants
Funding over time
peak $640K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,237,146 · 2
By mechanism
U44$837,532 · 1
R43$399,614 · 1
Investigators at Bioprovar Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients$461,487
U44 · FY2025 · AG
An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients$376,045
U44 · FY2021 · AG
An Innovative Immune Therapy Targeting the TREM1-Inflammation Pathway to Alleviate Excess Inflammation in Ulcerative Colitis of Geriatric Patients$221,111
R43 · FY2024 · AG
An Innovative Immune Therapy Targeting the TREM1-Inflammation Pathway to Alleviate Excess Inflammation in Ulcerative Colitis of Geriatric Patients$178,503
R43 · FY2025 · AG